Germ Cell Tumor and Testicular Tumor DNA Registry
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT02099734
- Status
- Recruiting
Conditions
- Germ Cell Tumor
- Testicular Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Questionnaires — BEHAVIORAL
- sample of blood or saliva — OTHERA sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
Study Details
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.
Key Dates
- Start date
- Jan 31, 2014
- Status verified
- Feb 2026
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: A: suspicion of germ cell tumor and/or a testicular masspatients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
- Arm: B: family members of Group Arelatives of patients with GCTs or testicular tumors
- Arm: C: healthy controls unrelated to Group A or Bhealthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
Primary Outcome Measure
creation of a Germ Cell Tumor and testicular tumor registry [ Time Frame: 5 years ]
Central Contacts
- Darren Feldman, MD646-422-4491
- Joel Sheinfeld, MD646-422-4311
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | - | Darren Feldman, MD 646-422-4491 |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | Darren Feldman, MD 646-422-4491 |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | Darren Feldman, MD 646-422-4491 |
| Cold Springs Harbor Laboratory (Specimen Analysis) | Cold Spring Harbor | New York | 11724 | Richard McCombie, PhD 516-367-8800 |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | Darren Feldman, MD 646-422-4491 |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | Darren Feldman, MD 646-422-4491 |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Darren Feldman, MD 646-422-4491 Joel Sheinfeld, MD 646-422-4311 Darren Feldman, MD (PRINCIPAL_INVESTIGATOR) |
| Memorial Sloan Kettering Nassau | Uniondale | New York | 11553 | Darren Feldman, MD 646-422-4491 |
Find similar trials in Basking Ridge, NJ
By research site
Memorial Sloan Kettering Basking Ridge· Basking Ridge, NJMemorial Sloan Kettering Monmouth· Middletown, NJMemorial Sloan Kettering Bergen· Montvale, NJCold Springs Harbor Laboratory (Specimen Analysis)· Cold Spring Harbor, NYMemorial Sloan Kettering Commack· Commack, NYMemorial Sloan Kettering Westchester· Harrison, NY
Related Studies
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursPHASE3 · Recruiting · University of Sydney · New York, New York
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPHASE3 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesPHASE1 · Recruiting · New York Medical College · Valhalla, New York
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsPHASE1 · Recruiting · Xencor, Inc. · Duarte, California